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Abstract 
Impaired peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
function has been demonstrated in several neurodegenerative diseases, and murine whole-body 
knockouts of PGC-1α have been considered as models for Huntington’s disease. Recent 
neuropathological studies, however, rather propose these animals to be morphological models 
of mitochondrial leukoencephalopathies, with special reminiscence of Kearns-Sayre syndrome. 
PGC-1α-deficient animals have already been subjected to behavioral assessments; however, the 
contradictory findings and the paucity of data assessing long-term progression necessitated 
further examinations. This study provides a comprehensive neurological phenotypic profiling 
of full-length-(FL-)PGC-1α-deficient mice in a broad age spectrum, with special focus on 
previously controversial findings, the issue of long-term phenotypic progression, the 
histopathological assessment of previously non-characterized tissues of potential 
clinicopathological relevance, and the gene expression profile of novel brain-specific isoforms 
of PGC-1α. Our findings demonstrate moderate hypomotility with signs of gait and trunk ataxia 
in addition to severe impairments in coordination and muscle strength in FL-PGC-1α-deficient 
mice, phenotypic features consistent of a mitochondrial disease. Intriguingly, however, these 
early alterations did not progress with age, the understanding of which may unveil mechanisms 
of potential therapeutic relevance, as discussed. The observed phenotype did not associate with 
retinal or spinal cord alterations, and was accompanied by mild myopathic changes. Based on 
these, FL-PGC-1α-deficient mice can be regarded not only as morphological but behavioral 
models of mitochondrial leukoencephalopathies, with an important temporal limitation that has 
now been clarified. The mechanisms capable of halting a potentially lethal phenotype are to be 
unveiled, as they may hold therapeutic value for mitochondrial diseases. 
Keywords: behavior, isoforms, pathology, PGC-1α, phenotype, progression. 
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Highlights: 
 FL-PGC-1α -/- mice have a symptomatology corresponding with mitochondrial 
encephalopathy. 
 The behavioral alterations intriguingly do not progress with age. 
 The alterations do not associate with retinal or spinal cord involvement. 
 The histopathology of skeletal muscle demonstrates only mild myopathic changes. 
 CNS-specific isoforms are the predominant PGC-1α mRNAs in the murine brain. 
 The NT isoforms are overexpressed in FL-PGC-1α -/- cerebella. 
Abbreviations: 
AD, Alzheimer’s disease 
ALS, amyotrophic lateral sclerosis 
CNS, central nervous system 
COX, cythochrome oxidase 
ERR, estrogen-related receptor 
FL-PGC-1α, full-length PGC-1α 
GFAP, glial fibrillary acidic protein 
HE, hematoxylin and eosin 
HD, Huntington’s disease 
KLB, Klüver-Barrera staining 
KSS, Kearns-Sayre syndrome 
LS, Leigh syndrome  
MEF2C, myocyte-specific enhancer factor 2C 
MELAS, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
MERRF, myoclonic epilepsy with ragged-red fibers 
MNGIE, mitochondrial neurogastrointestinal encephalopathy 
NARP, neuropathy, ataxia, retinitis pigmentosa 
NRF-1, and -2, nuclear respiratory factor 1 and 2 
NT-PGC-1α, N-terminal fragment of PGC-1α  
PPARγ, peroxisome proliferator-activated receptor-gamma 
PD, Parkinson’s disease 
PGC-1α, PPARγ coactivator 1-alpha 
RT-PCR, real-time polymerase chain reaction 
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1. Introduction 
Impaired mitochondrial function has widely been linked to the development of various 
neurodegenerative disorders, including Parkinson’s disease (PD), Huntington’s disease (HD), 
Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) [1-4]. These disorders are 
characterized by a relatively selective loss of neurons in different central nervous system (CNS) 
areas, corresponding to the leading clinical manifestations, in most of them with specific motor 
impairments. In addition, alterations of either nuclear or mitochondria genome affecting 
mitochondrial functions at various levels are pathognomonic of a group of congenital multi-
systemic diseases, collectively termed mitochondrial encephalopathies [5-8]. These diseases 
that include Kearns-Sayre syndrome (KSS), Leigh syndrome (LS), mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy 
with ragged-red fibers (MERRF), neuropathy, ataxia, retinitis pigmentosa (NARP), and 
mitochondrial neurogastrointestinal encephalopathy (MNGIE) generally present with a 
progressive symptomatology corresponding to the multi-systemic involvement of the brain, 
skeletal muscles, heart, and liver, among other less commonly affected organs [5-8]. The 
involvement of the brain manifests in different forms of mitochondrial encephalopathy in the 
different syndromes, commonly characterized by various extents of white matter vacuolation 
accompanied by reactive astrogliosis with or without apparent selective neurodegeneration in 
particular brain regions. 
Several lines of evidence indicate that peroxisome proliferator-activated receptor-
gamma (PPARγ) coactivator 1-alpha (PGC-1α), a nuclear-encoded coactivator of an armada of 
transcriptional factors that play extensive roles in the activation of adaptive mitochondrial 
responses, may contribute to the mitochondrial dysfunction in neurodegenerative disorders, 
including PD, AD, HD and ALS [1-5]. The coactivation of genes such as nuclear respiratory 
factor 1 and 2 (NRF-1, -2), estrogen-related receptors (ERRs), myocyte-specific enhancer factor 
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2C (MEF2C), and PPARs results in an enhanced expression of a wide spectrum of proteins 
involved in mitochondrial function and biogenesis [9], including mitochondrial replication and 
transcription, the import and assembly of respiratory complex subunits, a tissue-dependent 
induction of oxidative phosphorylation and thermoregulation, the enhancement of 
gluconeogenesis and fatty acid oxidation, as well as the increase of defense against oxidative 
stress [10, 11]. In line with these, experimental evidence suggest that pharmacological or 
transcriptional activation of PGC-1α may hold therapeutic value in neurodegenerative as well 
as mitochondrial diseases [11-13]. 
Despite its broad roles in mitochondrial functions, the absence of PGC-1α is compatible 
with life. The first pioneering publications with two independent murine PGC-1α knockout 
strains commonly described signs of striatal degeneration, proposing that these animals might 
model HD [14, 15], which corresponded with the findings of reduced striatal expression of 
PGC-1α and its target genes in the striatum of HD patients [16, 17] as well as in its transgenic 
in vivo [16-18] and in vitro models [16, 17] (comprehensively reviewed in [11]). Not doubting 
the potentially essential role of PGC-1α dysfunction in the pathogenesis of HD, the concept that 
PGC-1α-deficient animals themselves might model HD, however, has recently been questioned 
by serial findings of independent morphological and molecular biological analyses [19-21]. 
One of the two pioneering publications reported the development of a complete (i.e., with no 
residual expression) PGC-1α whole-body knockout strain, exhibiting hyperactivity with no 
overt muscle phenotype [14]. Though PGC-1α has recently been demonstrated to have a 
number of previously unknown isoforms [22], to the current knowledge, this strain can still be 
regarded as a complete knockout of PGC-1α [23]. Contrastingly, the second pioneering 
publication reported the development of another whole-body knockout strain demonstrating 
hypomotility and weakness [15], a strain later turned out to express a functional N-terminal 
fragment of PGC-1α (NT-PGC-1α) but not the full-length protein (FL-PGC-1α) [24]. This was 
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then followed by reports on muscle-specific complete PGC-1α knockouts with myopathic signs 
and weakness [25], as well as on complete whole-body and brain-specific PGC-1α knockouts 
failing to recapitulate hyperactive behavior [20, 26] but demonstrating impaired coordination 
[20] and ataxia proposed to be of cerebellar type [27]. Notably, the increasing behavioral data 
from the complete knockout phenotypes tend to delineate a phenotype resembling a relatively 
compensated mitochondrial disease. Correspondingly, recent neuropathological analyses on 
FL-PGC-1α -/- mice reported wide-spread, locally dramatic vacuolation of the white matter, 
predominantly affecting the thalamus, basal ganglia, internal capsule, pontomedullary 
brainstem as well as the cerebellum, accompanied by reactive astrogliosis in the brainstem and 
cerebellar nuclei [19]. In fact, this pathology is highly reminiscent of that seen in a human 
mitochondrial spongiform leukoencephalopathy, with particular resemblance to KSS [21]. 
Notably, no morphological correlates of striatal axonal or neuronal degeneration were apparent 
in FL-PGC-1α -/- animals [19] even at 75 weeks of age [21], which corresponds with earlier 
findings on young (postnatal day 10) FL-PGC-1α -/- animals via immunohistochemistry of 
striatal neurofilament [28] and has recently been confirmed by Lucas et al. demonstrating no 
significant loss of medium-sized spiny neurons via molecular biological methods in complete 
PGC-1α -/- mice [20]. Of note, the same group reported their observation of a relatively stable 
phenotype in complete PGC-1α -/- mice, with no robust progression between 4 and 12 weeks 
of age [20]. 
All these above detailed contradictory findings on PGC-1α-deficient mice and the recent 
report of a relatively stable phenotype in young PGC-1α -/- animals prompted us to perform a 
comprehensive profiling of motor phenotype of FL-PGC-1α -/- mice bred in our institute 
through a wide spectrum of age, with a special focus on the issue of phenotypic progression. 
The manuscript also addresses the expression profile of novel CNS-specific isoforms of PGC-
1α in FL-PGC-1α -/- mice (containing exon B4) [29], a feature previously not characterized in 
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this strain. As a supplement of prior published neuropathological findings on adult [19] and 
aged [21] FL-PGC-1α -/- brains, additional neuropathological work-up has been performed to 
better understand the potential background of the observed phenotypic alterations, including 
histopathological analysis of the retina, spinal cord and skeletal muscle. 
2. Materials and Methods 
2.1. Behavioral analysis 
2.1.1. Animals  
The study enrolled male FL-PGC-1α -/- (n = 20-24) and C57Bl/6J wild-type (n = 22–26) [15]. 
The animals were housed in cages (maximum 4 per cage) in standard conditions with 12-12 h 
light-dark cycle and ad libitum access to standard pellet food and water. The experiments were 
performed in accordance with the European Communities Council Directive (86/609/EEC) and 
were approved by the local Animal Care Committee. The study animals were randomized from 
a population ranging through a wide spectrum of age (10–90 weeks, overall means: 50.7 w 
(±2.6 w) FL-PGC-1α -/- vs. 50.5 w (±2.5 w) wild-type) to yield age-matched representative 
wide-age-range populations for the different methods applied. On assessing phenotypic 
progression, subgroups of the young and elderly halves of the above cohorts have been created 
(overall means: 30.1 w (±2.4 w) and 67.4 w (±2.5 w) FL-PGC-1α -/- vs 30.6 w (±2.5 w) and 
66.2 w (±2.2 w) wild-type for the young and elderly subgroups, respectively). The animals were 
placed in a transport room localized in the immediate vicinity of the examination room 12 hours 
prior to the behavioral examinations for adaptation to the examination conditions. The animals 
were examined during the same time of the day to minimize the influence of diurnal rhythm. 
The examination setups were cleaned with a solution containing 30% ethanol and were let dry 
completely after each session to avoid bias from olfactory cues. Standard light and temperature 
conditions were provided throughout the study. 
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2.1.2. Inverted screen test 
For the assessment of the skeletal muscle strength, we performed an inverted screen test along 
the principles described in [30], with slight modifications. Briefly, the examined animal was 
placed onto the top of a grid, which was then gently rotated by 180° (inverted) and fixed in a 
position 40 cm above a soft bedding of wooden chips abundantly applied (10 cm). The 
measurement was started immediately when the grid reached the inverted position and the 
latency to fall from the grid was recorded. The performance was measured in three consecutive 
sessions with 1-1 min relaxation time. The best performance was regarded as a correlate of 
muscle strength to rule out the influence of accidental falls due to potentially affected 
coordination. 
2.1.3. Open-field test 
For the assessment of spontaneous locomotor activity, a black box setup with an open field of 
48*48 cm and a side wall height of 36 cm was used, with the measurements performed along 
the principles previously described in [31]. Briefly, the examined animal was placed onto the 
middle of the field and let freely and spontaneously explore for 30 min. The movement pattern 
was recorded by built-in infrared led beams associated with the Conducta 1.0 software 
(Conducta 1.0 System, Experimetria Ltd., Hungary). The total distance ambulated (cm) and the 
total time spent with rearing (s) were parameters used for the analyses. The measurements were 
performed under indirect dim light (2.5 lux). 
2.1.4. Rotarod test 
For the assessment of motor coordination, a computer-assisted rotating rod with a diameter of 
3 cm and with an anti-slip ribbed surface located 25 cm above the bottom of the setup was used, 
with the measurements performed along the principles previously described in [32]. Briefly, 
the animals were trained on the rod on the two preceding days to learn the movement pattern 
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skill necessary to stay on the top of the rotating rod for longer periods. On the first training day 
a rotation speed of 5 rpm, whereas on the second day a speed of 10 rpm was applied for 5 min 
for three consecutive sessions with 30 min relaxation intervals. On the recording day, three 5 
min sessions with a gradually accelerating rod from 1 rpm to 30 rpm were used in a similar 
manner. The latency to fall from the rod was recorded by built-in infrared led beams associated 
with the TSE RotaRod Advanced software (TSE Systems, Bad Homburg, Germany). The mean 
performance was used for the analyses. 
2.1.5. Gait analysis 
For the assessment of gait pattern, a setup with a 6.5-cm-wide catwalk with a 40-cm-long 
recording area transparent from below, equipped with a video recording system using the 
Hypercam 1.6 software was applied (Hyperionics Technology, Murrysville, PA, USA). The 
measurements were performed along the principles described in [27], with modifications 
including the applied setup, the observer-controlled evaluation and the introduction of a novel 
standardized outcome parameter. The length of the recording area and the distance of the 
camera were adjusted and optimized to minimize spherical aberration. The catwalk was opaque 
from above and the sides to exclude visual bias. The examined animal was placed onto the 
catwalk and let freely and spontaneously explore the catwalk while recording. No visual or 
olfactory cues or any specific motivation were applied. The recording was stopped when the 
examiner managed to record 6 successful runs on-line. A run was regarded successful if the 
mouse moved through the recording area with an even speed, did not stop or turn before 
reaching the opposite end of the corridor, and did not make zigzag movements. The acquisitions 
were followed by an off-line re-evaluation of the runs, and eventually 4-6 successful runs per 
animal with an average of 14 strides could be used for further analysis. The video records were 
then subjected to a conversion to graphical images with colored dots indicating an anatomically 
standard region of each paw print and corresponding colored lines indicating the axis of 
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movement for each limb. The stride length and the base of support values were measured by 
ImageJ software (separately for the forelimbs and the hindlimbs, in both cases using the average 
of both sides). To rule out the potential bias arising from even subtle differences in size between 
the animals, a standardized measure (gait index) was introduced and defined as the ratio of the 
stride length and base of support. The average gait indices for both the forelimbs and the 
hindlimbs were used for the analyses. 
2.2. RT-PCR analysis 
Two FL-PGC-1α -/- and two wild-type 45-week-old mice were sacrificed and decapitated, and 
the striata, the overlying cortices and the cerebellum were dissected immediately on ice and 
placed to –80°C until use. Total RNA was isolated from the specimens using Trizol reagent 
(Invitrogen, USA) according to the manufacturer’s protocol. 1 µg of total RNA was reverse-
transcribed using random hexamer primers. Real-time polymerase chain reaction (RT-PCR) 
was performed on CFX 96 Real Time System (Bio-Rad, USA) to detect changes in mRNA 
expression, using various primer pairs at a final volume of 20 µl. Thermal cycling conditions 
for long products were 95°C for 10 min, followed by 40 cycles of 95°C for 10 s and 60°C for 
30 s, and 72°C for 1 min. Target gene expression was normalized to the endogenous control 
gene 18S. The relative mRNA level was calculated by the 2-∆∆Ct method. The relative 
expressions are presented in relation to the expression level of FL-PGC-1α mRNA transcribed 
from the reference promoter in the striatum of wild-type animals to allow comparison. The 
following primers were used: reference forward: 5’-
TGAGTCTGTATGGAGTGACATCGAGTG-3’; CNS-specific forward: 5’-
AATTGGAGCCCCATGGATGAAGG-3’; FL reverse: 5’- TTGGGGTCATTTGGTGAC-3’; 
NT-268 reverse (for wild-type mice): 5’-GGTCACTGGAAGATATGGC-3’; NT-254 reverse 
(for FL-PGC-1α -/- mice): 5’-TATCTTCTTGAGCATGTTGCG-3’. 
2.3. Histopathological work-up 
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The brains of two newborn mice were removed on ice and halved at the midline immediately 
after decapitation. Spinal cord segments from cervical, thoracic and lumbar regions of 8 wild-
type and 7 FL-PGC-1α -/- male mice aged 70-75 weeks were prepared on ice immediately after 
dissection. Eyes of 8 and 8 wild-type and 8 and 7 FL-PGC-1α -/- male mice aging 30 and 70-
75 weeks, respectively, were dissected immediately after decapitation. Quadriceps muscles 
were dissected from 4 wild-type and 3 FL-PGC-1α -/- male mice aging 50 weeks. Half brains, 
spinal cord segments and the eyes were fixed in 4% paraformaldehyde overnight and kept in 
15% glycerol in 4°C until embedding in paraffin. 3-μm-thick sections were stained with 
hematoxylin and eosin (HE) and Klüver-Barrera (KLB; Luxol and Fast red) stainings, and the 
anti-glial fibrillary acidic protein (GFAP; 1:3000, Dako, Glostrup, Denmark) polyclonal 
antibody was used for the visualization of astroglial reaction in the newborn brains. The DAKO 
EnVision detection kit, peroxidase/DAB, rabbit/mouse (Dako) was used for visualization of 
antibody reactions. The quadriceps specimens were snap-freezed in isopentane cooled with 
liquid nitrogen immediately after dissection, and stored in –80°C until embedding. In addition 
to HE staining, we performed enzyme histochemistry for cytochrome c oxidase (COX). 
2.4. Statistical analyses 
The analyses of the obtained parameters were performed by the use of SPSS 22.0 program. The 
distribution of each dataset was assessed by normality analysis by the use of Shapiro-Wilk test. 
The comparison of continuous variables with normal distribution was performed by the 
parametric Student’s unpaired t-test using also the Levene’s test for the assessment of the 
equality of variances, whereas variables showing non-normal distribution were compared by 
the Mann-Whitney U test. In case of correlation analyses, variables with normal distribution 
were subjected to Pearson’s correlation, whereas Spearman’s rank correlation was performed 
in case of non-normal distribution. To control the analyses for potential confounding effect of 
age and to estimate the effect sizes of variables with significant between-group differences, 
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binary logistic regression analyses were performed. Multiple comparisons of pre-defined 
subgroups of age were performed via the parametric one-way analysis of variance (ANOVA) 
or the non-parametric one-way Kruskal-Wallis test based on the normality of data, followed by 
corresponding pairwise post hoc analyses with p values corrected for multiple comparisons by 
the method of Bonferroni. Data are presented as mean (± standard error of mean) or median 
[intequartile range] for variables with normal and non-normal distribution, respectively. A p 
value < 0.05 was regarded as significant. 
3. Results 
3.1. Behavioral analysis 
FL-PGC-1α -/- animals demonstrated remarkably poorer performance on the inverted screen 
compared to their wild-type counterparts with significantly shorter latency to fall from the grid 
(p = 0.001; 33.5 s [15.25 s – 84.25 s] vs 99.5 s [51.0 s – 231.75 s]; Fig. 1A). The worse 
performance of FL-PGC-1α -/- animals was not attributable to an increased body weight, 
contrastingly, FL-PGC-1α -/- animals showed a tendency towards decreased body weight 
compared to controls (p = 0.076; 27.70 g [26.17 g – 28.63 g] vs 28.31 g [27.12 g – 31.13 g]). 
Notably, while the between-group difference of body weights per se was not statistically 
significant due to the substantial overlap within the wide age range (21-34 g), the logistic 
regression analysis identified body weight as a significant predictor of genotype (p = 0.030, 
Wald = 4.712) with an Exp(B) = 1.141 (95% confidence interval (CI) = 1.034–1.934) when the 
analysis was controlled for age as a confounder, representing a 14.1% increase in the odds of 
being wild-type with each gram elevation of bodyweight. Proposing that body weight may 
influence the measurement of grip strength in a setup such as the inverted screen, the estimation 
of the effect size in this case was controlled for both age and body weight as potentially 
confounding covariates in a binary logistic regression model, which detected the latency to fall 
performance as a significant predictor of the genotype (p = 0.010, Wald = 6.644) with an Exp(B) 
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= 1.011 (95% CI = 1.003–1.020), calling for a 1.1% increase in the odds for an animal to be 
wild-type with every additional second spent on the grid. Unexpectedly, the decreased 
performance in the inverted screen did not show any clear association with age (Table 1); 
likewise, no significant difference could be observed between the young and elderly subgroups 
in either group (p > 0.05 for all post hoc analyses). 
In addition to signs of decreased strength, FL-PGC-1α -/- animals showed significantly reduced 
ambulatory behavior manifesting in modestly decreased ambulation distance (p < 0.001; 
6341.0 cm (±472.9 cm) vs 9026.7 cm (±509.5 cm); Fig. 1B) and markedly reduced time spent 
with rearing (p < 0.0001; 116.8 s [46.7 s – 150.0 s] vs 210.4 s [160.0 s – 237.3 s]; Fig. 1C). The 
binary logistic regression analyses detected both of these parameters as significant predictors 
of genotype, with every additional meter distance ambulated increasing the odds of being wild-
type with 5.1% (p = 0.002, Wald = 9.429, Exp(B) = 1.051 (95% CI = 1.018–1.084)) and every 
additional second spent with rearing increasing the odds of being wild-type with 3.5% (p < 
0.001, Wald = 11.919, Exp(B) = 1.035 (95% CI = 1.015–1.055)) during the 30 min recording 
period, when controlling for age. These parameters, however, also did not demonstrate any 
progression with age (Table 1) and no significant differences could be observed between young 
and elderly subgroups in either group (p > 0.05 for all post hoc analyses). 
On assessment of motor coordination, the average performance of FL-PGC-1α -/- mice in the 
accelerating rotarod was remarkably lower than that of the wild-type mice (p < 0.0001; 27.3 s 
[10.9 s – 74.8 s] vs 137.3 s [95.1 s – 168.8 s]; Fig. 1D). Age-controlled logistic regression 
analysis revealed the average latency to fall from the rod as a significant predictor of genotype 
(p < 0.001, Wald = 10.982) with an Exp(B) = 1.030 (95% CI = 1.012–1.048), which calls for a 
3.0% increase in the odds for an animal to be wild-type with every additional second spent on 
the rod. Though this feature did show significant negative association with age among wild-
type animals, it did not show any progression with age among FL-PGC-1α -/- mice (Table 1), 
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and likewise, significant difference could only be observed between young and elderly wild-
type (p = 0.041) but not FL-PGC-1α -/- animals (p > 0.05). 
The gait analysis of the animals revealed significantly decreased gait indices corresponding to 
widened bases of support in FL-PGC-1α -/- mice, a feature also consistent with ataxia. The 
differences were comparable as regards the forelimbs (p = 0.003; 3.44 (±0.14) vs 4.08 (±0.14)) 
and in the hindlimbs (p = 0.018; 1.76 (±0.09) vs 2.05 (±0.08); Fig. 1E-F), with age-controlled 
logistic regression analyses revealing 16.0% (p = 0.008, Wald = 7.057, Exp(B) = 1.160 (95% 
CI = 1.040–1.294)) and 21.7% (p = 0.024, Wald = 5.079, Exp(B) = 1.217 (95% CI = 1.026–
1.444)) increases in the odds of being wild-type with every 0.1 arbitrary unit elevation in 
forelimb and hindlimb gait indices, respectively. Neither the hindlimb nor the forelimb gait 
index showed any association with age (Table 1), and the subgroup analyses between young 
and elderly animals did not show difference either (p > 0.05 for all post hoc analyses). 
3. 2. Histopathological work-up 
Histopathological analysis of different spinal cord segments revealed no apparent involvement 
of the spinal white matter tracts in the vacuolar change previously found to be prominent in 
certain CNS regions of FL-PGC-1α -/- mice (Fig. 2A-B). Likewise, no vacuolar alterations were 
observed in the brains of newborn FL-PGC-1α -/- mice (Fig. 2C-D), and no signs of reactive 
astrogliosis were apparent in the newborn brainstem (data not shown), a feature characteristic 
of adult FL-PGC-1α -/- animals. Histology of the eyes demonstrated no signs of retinal 
degeneration in FL-PGC-1α -/- mice at any age; in particular, the outer nuclear layer showed 
no signs of neuronal degeneration (i.e., that of retinitis pigmentosa), a feature characteristic of 
certain mitochondrial cytopathies, particularly the KSS. On histological and 
enzymehistochemical analysis of the quadriceps muscles, both the wild-type and the FL-PGC-
1α -/-mice showed fibers with enhanced subsarcolemmal accumulation of mitochondria (data 
not shown); however, we did not observe complete COX-deficient fibers in the COX staining 
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(Fig. 2E-F; inlet in lower right quadrant). In the FL-PGC-1α -/- mice, we observed mild caliber 
changes together with enhanced internalization of nuclei. There was a lack of highly atrophic 
fibers or grouping of atrophic fibers (Fig. 2E). In sum, we interpreted these findings as mild 
myopathic changes in FL-PGC-1α -/- mice. 
3. 3. RT-PCR analysis 
FL-PGC-1α -/- animals demonstrated diminished expression of FL-PGC-1α isoforms 
transcribed from either the reference promoter or from the CNS-specific promoter (Fig. 3), 
demonstrating that the nomenclature of FL-PGC-1α -/- in this strain is appropriate, even in light 
of the recently discovered CNS-specific isoforms of PGC-1α [29]. The expression levels of 
CNS-specific isoforms were remarkably higher in all examined brain regions as compared with 
that of the isoforms transcribed from the reference promoter; this was true for both the FL and 
the NT isoforms in the wild-type and the NT-254 isoform in FL-PGC-1α -/- animals. The 
highest levels of expression were consistently detected in the cerebellum for both the FL- and 
the NT isoforms, independently of the promoter of transcription. The expression of the NT-254 
isoform was comparable in FL-PGC-1α -/- mice to that detected in wild-type animals in the 
striatum and the cortex; however, it was remarkably upregulated in the cerebellum of FL-PGC-
1α -/- mice compared to wild-type counterparts (Fig. 3). 
4. Discussion 
Recent neuropathological analyses on FL-PGC-1α-deficient mice revealed a pathology highly 
reminiscent of KSS [19] even at the ultrastructural level [21], suggesting that PGC-1α-deficient 
murine strains might serve as models for mitochondrial diseases. However, based 
predominantly on vacuolation and astrogliosis reported in the striatum, former studies on the 
complete PGC-1α as well as the FL-PGC-1α whole-body knockout strains had proposed that 
PGC-1α-deficient mice could be regarded as models of HD [14, 15]. This well corresponded 
16 
 
with the findings of impaired striatal expression of PGC-1α and many of its target genes in the 
striatum of HD patients, transgenic animals and in cell cultures (reviewed in [11]). Furthermore, 
this concept was claimed to be supported phenotypically by the finding of hyperactivity – 
without apparent weakness – in the complete PGC-1α -/- strain, which was considered to be 
typical of HD [14]. Since then, the vast majority of scientific reports dealing with PGC-1α 
associates its deficiency with striatal neurodegeneration and HD features. However, a number 
of contradictions accompany these observations, and increasing amount of studies tend to 
question this concept. First, it should be noted that repeated and comprehensive 
neuropathological analyses of FL-PGC-1α-deficient mice demonstrated no direct or indirect 
signs of striatal neurodegeneration in the striatum (including also the complete lack of astroglial 
reaction even at the oldest age group analyzed in this study) [19, 21], which findings were 
supported by an independent study on the complete PGC-1α-deficient strain using molecular 
biological techniques [20], and by another group by the use of neurofilament 
immunohistochemistry [28]. Based on our recent ultrastructural and immunohistochemical 
analysis, vacuolation in the striatum (and also in several other regions) indeed appears to be of 
myelinic (most probably oligodendroglial) origin, alterations which are characteristic of 
mitochondrial and other metabolic diseases, and which cannot be regarded as signs of 
neurodegeneration [21]. Secondly, the translatability of hyperactivity (i.e., increased 
locomotion) observed in the complete PGC-1α -/- strain to hyperkinetic movement disorders 
(i.e., chorea and ballism) characteristic of human HD is questionable. Indeed, though early 
studies with isolated local intrastriatal lesions by excitotoxins such as quinolinic or kainic acid 
lead to either spontaneous or amphetamine-induced increased locomotor behavior [33, 34], 
systemic toxin-induced or transgenic murine models of HD generally present with a phenotype 
characterized by markedly decreased rather than increased locomotor performance [31, 32, 35, 
36]. Contradictory enough, the other pioneering study examining the FL-PGC-1α-deficient 
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strain reported hypomotility and weakness as opposed to hyperactivity observed in the complete 
knockout [14, 15], a difference that is hard to explain merely by the different genetic 
engineering background. Notably, a muscle-specific variant of the proposedly hyperactive 
complete PGC-1α -/- strain exhibited decreased locomotion and muscle strength, similarly to 
the FL-PGC-1α -/- strain [37]. Furthermore, a more recent studies on the complete whole-body 
as well as the brain-specific PGC-1α -/- strains did not reveal signs of increased locomotion 
[20, 26], but observed decreased exploratory behavior by means of a diminished ability to rear 
[20], further increasing the number of contradictions in PGC-1α-related literature. It is also of 
note, that though there was a study examining signs phenotypic progression at an early age of 
development [20], no studies have been reported dealing with phenotypic progression on longer 
scales. 
All these above detailed contradictions and the paucity of long-term phenotypic 
progression studies prompted us to examine the FL-PGC-1α -/- population bred in our institute 
with a battery of methods profiling motor phenotype, with special attention to the issue of 
phenotypic progression via enrolling age-matched male mice from a wide range of age. The 
motor phenotype was profiled on the axes of muscle strength, spontaneous locomotion and 
ataxia/motor coordination. The inverted screen test demonstrated consistently and markedly 
shorter latency to fall for FL-PGC-1α -/- mice compared to wild-type counterparts, a feature 
indicative of decreased muscle strength. The shorter latency to fall was not related to increased 
body weight as it could have been proposed; quite contrary, the FL-PGC-1α -/- mice had a 
consistent tendency of decreased body mass, which covariate was indeed a significant predictor 
of the genotype when controlling for the age of the animals. This observation corresponds with 
studies describing tendencies of decreased body weight in complete PGC-1α -/- mice [14, 27, 
38], but contradicts with a prior study on FL-PGC-1α -/- mice reporting decreased body weight 
only in the first weeks of life, and increased body weight values at later ages [15]. Based on the 
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findings that muscle-specific PGC-1α -/- mice exhibit decreased body weight [25] and that 
brain-specific PGC-1α -/- animals exhibit similar body weight to their controls [26], this lean 
phenotype could as well be attributable to myopathy (as demonstrated by prior biochemical and 
gene expression analyses [14, 15, 25, 38]) and subsequent muscle atrophy corresponding to a 
wasting condition due to chronic mitochondrial disease. However, this hypothesis could not be 
fully confirmed by current histopathological analyses of quadriceps muscles, demonstrating 
only mild myopathic changes in the PGC-1α-deficient animals without overt signs of 
mitochondrial muscle disease and/or neurogenic atrophy, corresponding with prior reports on 
younger animals [14, 15, 25, 38]. Although we observed a certain amount of subsarcolemmal 
mitochondria in both the wild-type and FL-PGC-1α -/- mice, there were no COX-negative 
fibers; therefore, we could not define these as unequivocal histopathological evidence for a 
mitochondrial myopathy. These altogether also suggest that the weak phenotype observed in 
FL-PGC-1α -/- mice may either be predominantly attributed to the CNS alterations or at most 
influenced by a functional muscle disorder with only mild pathological correlates. Along these 
lines, the robustly decreased total time of rearing, as observed in the open-field paradigm, may 
also be suggestive of a weakening of the axial muscles in FL-PGC-1α -/- mice; however, it may 
also be accounted for by trunk ataxia due to the apparent cerebellar involvement [19, 21, 27]. 
The predominant involvement of the central lesions in the decreased ability to rear is supported 
by similar findings on brain-specific complete PGC-1α -/- mice [20]. The remarkably decreased 
performance on the rotarod, a test traditionally applied to measure motor coordination (i.e., 
ataxia), can be explained in particular by neuronal degeneration reported in the brainstem and 
the cerebellum, as well as the robust myelin vacuolation in the basal ganglia [19, 27]. A similar 
decrease in rotarod performance has also been described in the CNS-specific conditional 
knockout variant of the complete PGC-1α -/- strain [20], which also calls for a dominant role 
of CNS alterations underlying the observed movement disorder. An impaired coordination in 
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FL-PGC-1α -/- mice was also represented by significantly decreased gait indices observed in 
our gait analysis, manifesting in widened bases of support accompanied by relatively preserved 
stride lengths in both the fore- and the hindlimbs, a feature consistent with ataxia. In accordance 
with these, a recent study on the complete PGC-1α -/- strain assessing the gait pattern of 24-
week-old mice in an automated catwalk system revealed multiple alterations in gait pattern also 
characteristic of ataxia, which phenotype was linked to the degeneration and loss of cerebellar 
Purkinje cells [40]. All these correspond well to the concept proposing PGC-1α-deficient strains 
as models for mitochondrial encephalopathy, especially since the neuropathological alterations 
described by our group on FL-PGC-1α -/- mice were remarkably reminiscent of that seen in 
KSS [19, 21], a mitochondrial disease where the overt loss of Purkinje neurons is virtually 
pathognomonic [7, 21, 39, 40]. The significance of this  
The observation that the mRNA expression levels of both the FL and the NT isoforms of 
PGC-1α either transcribed from the reference or the CNS-specific promoter are the highest in 
the cerebellum in wild-type C57Bl6/J mice, an observation recapitulating and extending prior 
findings in rats [41], together with the findings of multiple degenerative alterations reported in 
this region in PGC-1α-deficient mice [19, 21, 27], place the cerebellum in the potential center 
of relevance in the phenotype associated with PGC-1α deficiency. This concept gains further 
support by our observation of a remarkable upregulation in the expression of the residual NT-
254 fragment in the cerebellum but not in the other examined CNS regions of FL-PGC-1α -/- 
mice, suggesting the existence of a functional feedback mechanism confined to this brain 
region, which may result in a compensatory elevation of PGC-1α in case of compromised 
mitochondrial function. A similar cerebellum-predominant upregulation of PGC-1α isoforms 
has also been observed in our prior report in transgenic HD mice [18]. The higher levels of 
expression of the CNS-specific isoforms in the wild-type mice are consistent with that observed 
previously in human brains [29]. 
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The observed clinical phenotype of FL-PGC-1α -/- mice altogether with impaired muscle 
strength, decreased locomotion, disturbed coordination and ataxic gait, especially in light of the 
decreased body mass, is consistent with a phenotype expected in mice with a chronic systemic 
mitochondrial disease. Supplementing prior neuropathological analyses that revealed 
widespread white-matter vacuolation and signs of neuronal degeneration in the brainstem and 
the cerebellum of PGC-1α-deficient mice [19, 21, 27], our current histopathological analysis 
revealed that the observed phenotypic alterations were not associated with signs of retinal 
involvement, a characteristic feature of KSS. This is consistent with our findings of preserved 
spatial memory by the use of visual cues in FL-PGC-1α -/- mice (unpublished observation), 
suggesting that the observed phenotypic changes may not be influenced by visual deficits. 
Furthermore, we also did not observe apparent myelinopathy or neurodegeneration in the spinal 
cord of FL-PGC-1α -/- mice, excluding morphological evidence of a potential involvement of 
the spinal cord in the observed phenotype, with particular regards to ataxia. The identification 
of a potential model of mitochondrial encephalopathies is of significance because the majority 
of genetically engineered animals targeted at nuclear genes involved in disease-causing 
mutations resulted in early postnatal or embryonic lethality, whereas most viable strains have 
no neuropathology, rendering the modeling of this group of diseases rather difficult (reviewed 
in detail in [19]). Importantly, some of these disease-causing genes with reported knockouts are 
under the regulation of PGC-1α, including POLG-1 [42], ANT-1 [43], and MFN1 [44] and 2 
[45]. Of note, knockouts of several other genes not yet identified as subjects of disease-causing 
mutations are also considered as animal models of mitochondrial diseases, which include the 
PGC-1α-regulated genes Tfam and SOD2 [46]. Fascinatingly, conditional knockout of Tfam 
has been dedicated as a model of KSS cardiomyopathy [47]; whereas SOD2-deficiency has 
been reported to resemble Leigh’s encephalopathy [48]. Notably, PGC-1α-deficient animals 
nicely recapitulate key features of Tfam-deficient hearts [38] as well as SOD2-deficient brains 
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[19], in line with the decreased expression of Tfam [38] and SOD2 [10] in these animals. Based 
on all these, we believe that PGC-1α-deficient mice with a reasonable pathogenic factor and a 
highly reminiscent phenotype can be a useful animal model for mitochondrial disease, with 
particular regards to KSS. Though FL-PGC-1α-deficient mice have been not associated with 
large-scale mtDNA deletions typical of KSS [23], their phenotype is associated with perturbed 
mtDNA replication (with a decreased mtDNA amount) [38] as well as a globally increased 
oxidative stress [10], which together may be speculated to be predominantly accounted for the 
observed CNS phenotype. 
In addition to the supplementation and in part confirmation of findings of prior studies on 
FL-PGC-1α -/- mice, our results demonstrate previously unrevealed commonalities with 
features of the complete PGC-1α -/- strain, such as impaired motor coordination/ataxia and 
decreased body weight, suggesting that the two whole-body knockout strains might not differ 
from each other as much as it was originally proposed in terms of the general locomotor 
phenotype. As a second main novelty, however, our results demonstrate that the observed 
phenotypic alterations, which are present even in the earliest ages examined, unexpectedly did 
not progress further with time. Though a similar observation has already been reported with 
complete PGC-1α -/- mice (both whole-body and brain-specific conditional knockouts), the 
oldest animals in that study were 12 weeks old [20], which is consistent with the age of the 
youngest animals examined in our study cohort. To our knowledge, the examination of PGC-
1α-deficient animals up to 90 weeks of age is unprecedented. The explanation for this non-
progressive nature of phenotype after a certain age is currently unrevealed, and is presumably 
attributable to the activation of salvage pathways that can compensate for the loss of function 
of PGC-1α protein. It can also be proposed that PGC-1α itself is only essential for early 
postnatal development, and not for embryonal or later postnatal (i.e., adult) life. This is 
consistent with a thermoregulatory deficit observed only in PGC-1α-deficient younglings but 
22 
 
not in adult mice [15], the elevated mortality of puppies ([14], corresponding to our unpublished 
observation with this strain) accompanied by a normal number of newborns in the litter [14, 15] 
and an apparently unaffected life expectancy thereafter, and is also in accordance with the lack 
of neuropathological alterations in newborn brains confirmed by our current study. These all 
nicely correspond with the findings of a comprehensive study demonstrating largely diminished 
PGC-1α expression in the brain of adult rats at the protein level, with the highest expression 
reached during late embryonal and early postnatal development [41]. Of note, this early 
postnatal period also corresponds with the peak of mammalian myelinogenesis, which is 
consistent with an impaired myelin production in FL-PGC-1α -/- mice as early as postnatal day 
10 [28], and may also explain the lack of myelin vacuolation in the newborn mice. It would be 
fascinating to see whether this long-term non-progressive nature of motor phenotype is present 
in complete PGC-1α -/- animals (either whole-body or tissue-specific knockouts), which could 
exclude the potential compensatory role of downstream factors coactivated by the NT isoforms 
readily expressed by FL-PGC-1α -/- animals examined in our study. The revelation of such 
compensatory mechanisms that are able to withhold a robust early onset pathology as seen in 
PGC-1α-deficient mice might be of therapeutic relevance in disorders where mitochondrial 
function is compromised, especially in those where the involvement of PGC-1α dysfunction 
has already been established. 
5. Conclusion 
We conclude that FL-PGC1α -/- animals and the applied behavioral assessment techniques can 
be suitable for pharmacobehavioral studies with a therapeutic aim in mitochondrial 
encephalopathies, as they exhibit several clinical and neuropathological phenotypic hallmarks 
of such diseases. This is of importance because of the paucity of viable animal models that 
exhibit both morphological and behavioral symptoms of a mitochondrial disease. An important 
limitation revealed, however, in our study is that the potential treatments should be initiated in 
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the earliest age possible, as motor alterations that have already been developed do not progress 
any further. The mechanisms underlying this compensation are to be revealed, as they may 
provide information of therapeutic relevance in this currently intractable group of neurological 
diseases. 
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Table 1. 
 
A Latency to fall from the grid 
in light of age 
B Ambulation distance                  
in light of age 
WT FL-PGC-1α -/-  WT FL-PGC-1α -/- 
Rho -0.093 0.365 Rho 0.111 0.388 
p 0.652 0.079 p 0.606 0.074 
n 26 24 n 24 22 
C Rearing time                             
in light of age 
D Latency to fall from the rod      
in light of age 
WT FL-PGC-1α -/-  WT FL-PGC-1α -/- 
Rho 0.264 0.328 Rho -0.560** -0.126 
p 0.213 0.136 p 0.007 0.598 
n 24 22 n 22 20 
E Forelimb gait index                 
in light of age 
F Hindlimb gait index                 
in light of age 
WT FL-PGC-1α -/-  WT FL-PGC-1α -/- 
Rho -0.089 - 0.012 Rho -0.022 0.263 
p 0.686 0.958 p 0.921 0.249 
n 23 21 n 23 21 
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Figure and table captions 
 
Fig. 1. Phenotypic profile.  
FL-PGC-1α -/- mice exhibit remarkable reduction in muscle strength (A) with asthenia, 
decreased spontaneous locomotion (B) and rearing (C), which were accompanied by impaired 
motor coordination (D) with decreased gait indices (E and F) consistent with widened bases of 
support as visualized by the representative gait traces (G), indicative of ataxia. Abbreviations: 
WT, wild-type; SL, stride length; FBS, forelimb base of support; HBS, hindlimb base of 
support. 
 
 
Fig. 2. Histopathological work-up.  
Neuropathology of FL-PGC-1α -/- mice does not associate with vacuolar change in the white 
matter of the spinal cord (A, longitudinal section, HE; B, cross-section, KLB) as compared with 
prominent myelin vacuolation demonstrated previously in the brain. Newborn FL-PGC-1α -/- 
mice are free of myelin vacuolation in areas robustly affected in adult and aged FL-PGC-1α -/- 
mice (C, retroflex fascicle, HE; D, internal capsule, HE). No signs of retinal degeneration are 
apparent in FL-PGC-1α -/- mice (F, HE) as compared with wild-type counterparts (E, HE). 
Compared to wild-type animals (G), the quadriceps muscle of FL-PGC-1α -/- mice exhibits 
mild myopathic changes with caliber discrepancy and enhanced internalization of nuclei (H, 
HE); however, without the presence of COX-negative (inlet in the lower right quadrant) or 
highly atrophic fibers, we could not interpret these as unequivocal evidence for a mitochondrial 
myopathy. 
 
 
Fig. 3. PGC-1α isoform analysis. 
RT-PCR analysis demonstrates diminished FL-PGC-1α mRNA expression both from the 
reference promoter and the novel CNS-specific promoter. The highest expression of PGC-1α 
isoforms in wild-type mice associates with the cerebellum. The expression levels of CNS-
specific isoforms are higher in all brain regions as compared with those transcribed from the 
reference promoter. The NT-PGC-1α isoforms are dramatically upregulated in the cerebellum 
of FL-PGC-1α -/- mice, possibly representing a functional feedback mechanism confined to 
this region. 
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Table 1. Progression analyses. 
Correlation analyses demonstrate no statistically significant negative association with age in 
any of the assessed behavioral parameters in FL-PGC-1α -/- mice (A-F). These data correspond 
with that obtained from multiple comparison analyses between young and elderly subgroups, 
indicating the lack of evident phenotypic progression in FL-PGC-1α -/- mice. 
